Clinical Trial Update: PR3-AAV Resilient Remission or PRRR [Phase 2]

View source ↗

Summary

A Phase 2 trial of PR3-AAV Resilient Remission (PRRR) for ANCA-associated vasculitis, including granulomatosis with polyangiitis and microscopic polyangiitis, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anca-associated Vasculitis
• Granulomatosis with Polyangiitis
• Microscopic Polyangiitis

Drugs mentioned

• PR3-AAV Resilient Remission (PRRR)

Snippet

Sponsor: Mayo Clinic | Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis | Phase 2 | Status: TERMINATED | Results posted: 2024-07-31